The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about many questions as hospitals and blood centers prepare to order the testing. We've put together a FAQ document to clarify what we know today. We will update the document as we get more information on existing questions and as new questions get asked, and will update the blog with the revised FAQ document.
Thanks for your support as we work to rapidly get this testing available to you. You can find the FAQ document here: CTS COVID-19 Questions and Answers
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...